Epigenomics AG: Epigenomics AG Successfully Completes Capital Increase

Press release

Epigenomics AG Successfully Completes Capital Increase

• Total gross proceeds of EUR 4.9 million raised in a rights issue
• Transaction significantly over-subscribed
• Use of proceeds to finance market introductory measures for Epi proColon(R) in the U.S.

Not for distribution in the United States

Berlin (Germany) and Germantown, MD (U.S.A.), May 28, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced the successful completion of a capital increase by way of a rights issue.

“We are overwhelmed about the outcome of this financing, which was significantly over-subscribed, and thank all of our shareholders who participated in the capital increase for their trust and commitment,” commented Dr. Thomas Taapken, CEO/CFO of Epigenomics. “We are convinced that the results of the ADMIT study with nearly 100% adherence rate for Epi proColon(R) will support our pre-market approval (PMA) application for our test. We recently submitted the data to the FDA and will discuss these results with the agency over the next few weeks. The proceeds of this financing will support us in strengthening our manufacturing capabilities and fuel our activities to introduce our blood-based test for colorectal cancer screening to the U.S. market, once it is approved.”

Transaction outline:

On May 28, 2015, the Executive Board of Epigenomics AG announced that the Company will fully implement the capital increase as announced on May 11, 2015, hereby raising gross proceeds in the total amount of EUR 4,999,997.44. These proceeds extend, based upon current projections, the cash runway of the Company at least into Q2 2016, assuming complete conversion of all outstanding convertible bonds by the end of 2015.

Today, the Executive Board of the Company, with the approval of the Supervisory Board, resolved on the increase of the Company’s share capital in the amount of EUR 976,562.00 by issuing 976,562 new no-par value registered shares (“Namensstückaktien”) representing a notional portion of the share capital of EUR 1.00 per share from the Company’s Authorized Capital 2014/II. The details of the capital increase were announced on May 11, 2015 via ad-hoc notification.

All of the 976,562 new registered shares that have been offered during the subscription period from May 13, 2015 until May 27, 2015 were taken up by existing shareholders of the Company at a subscription price of EUR 5.12 per share. The technical implementation of the capital increase was conducted by Bankhaus Neelmeyer.

Subject to the registration of the implementation of the capital increase with the commercial register (“Handelsregister”) the admission of the new shares to the regulated market (“regulierter Markt”), Prime Standard, of the Frankfurt Stock Exchange is expected on or around June 9, 2015. Trading in the new shares is expected to begin on June 11, 2015, and delivery of the new shares to the investors is expected on June 11, 2015.

In line with previous announcements, Epigenomics will continue to diligently explore and potentially execute all strategic options for the Company. These options especially include the possibility of securing additional financial resources to support the Company’s operations up to and beyond a potential U.S. Food and Drug Administration (FDA) approval for Epi proColon(R).

– Ends –

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing innovative products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe, has received approval by the Chinese Food and Drug Administration for China and is under regulatory review by the U.S. Food and Drug Administration (FDA). Additionally, the Company markets its tissue assay for use in lung cancer diagnosis, Epi proLung(R), in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
pr@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.